Nirmatrelvir-ritonavir, sold by Pfizer under the name Paxlovid, is commonly prescribed to treat COVID-19. When treating some heart patients, however, physicians may want to consider an alternative approach.

Researchers explored data from nearly 20,000 patients, sharing their findings in Annals of Internal Medicine.

Deepak Bhatt, MD, a professor of medicine at Harvard Medical School, details the new generation of cholesterol-lowering agents and their roles in patient care. 

“This systemic failure is a global tragedy, as many premature deaths from CVD could be avoided,” one cardiologist said. 

Manufacturers, it seems, are unable to keep up with high demand. 

The new meta-analysis, published in Frontiers in Cardiovascular Medicine, included data from 58 million patients. “We hope our findings will help mitigate vaccine hesitancy and increase vaccine uptake," one researcher said. 

A team of specialists from Cleveland Clinic reviewed nearly 3,000 medications, writing that a common type 2 diabetes medication offered the most potential as an effective treatment for AFib. 

A well-known cardiologist who once fully supported COVID-19 vaccines is now saying he thinks they have done more harm than good. Online, as one might expect, people on both sides of this particular debate have been quick to respond.